To Evaluate the Safety and Efficacy of TD0015 Pilulae in Patients with Knee Osteoarthritis

Last updated: October 23, 2024
Sponsor: Sao Thai Duong Joint Stock Company
Overall Status: Active - Recruiting

Phase

2

Condition

Osteoarthritis

Knee Injuries

Treatment

TD0015 Placebo

TD0015

Clinical Study ID

NCT06657495
TD0015
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Preclinical trials in animal models have suggested that the estimated dose of TD0015 in clinical presents no safety concerns.The investigational product is TD0015 pilulae, which is based on the traditional prescription named "Độc hoạt tang ký sinh thang" (Thien Kim Phuong).

The traditional prescription has the effect of circulating blood in the tendons and bones to bring out evil spirits, blood tonic, kidney tonic to prevent recurrence of diseases and against joint degeneration, joint deformation, muscle atrophy, stiffness to recover normal joint function.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Male or female patients ≥ 18 years old must meet ALL or the following criteria clusters 1,2,6 or 1,3,5,6 or 1,4,5,6 to be enrolled:

  1. Knee pain

  2. Bone spurs forming along the edges of the joint, narrowing of joint space in X-rayfilm (grade I-III) according to Kellgren and Lawrence

  3. Knee joint effusion

  4. Morning stiffness that lasts less than 30 minutes when moving

  5. Knee crepitus when moving

  6. Patient voluntarily agree and and sign in the ICF

According to traditional medicine: The disease type is Wind-Cold-Damp Bi with Kidney and Liver Deficiency. Symptoms are knee joint is pain, cold and heavy. Pain is usually fixed, little movement, mild during the day, severe at night, increased in cold and wet weather. Warm compresses to relieve pain, knee joint may be swollen, limited movement, may have morning stiffness, joint deformity associated with muscle atrophy, back pain, not warm limbs.The tongue is pale, the tongue is white and greasy, and deep-thready-weak pulse.

Exclusion

Exclusion Criteria:

  1. Hypersensitivity to any subtances of TD0015 pilulae.

  2. Pregnant or lactating

  3. Currently having surgical indications.

  4. Other conditions asseted by the investigator that are not eligible to be enrolled.

  5. Knee Osteoarthritis grade IV according to classification of Kellgren and Lawrence (specify that large osteophytes, marked narrowing of joint space, severe sclerosisand definite deformity of bone ends)

  6. Self-administration of other anti-inflammatory medicine (except for NSAIDs) duringstudy period as for 3 arms

  7. Patient is treated by NSAIDs within 3 days or has corticosteroid Intra-articularinjection within 3 months prior to enrolment

  8. Joint and/or systemic infections

  9. Cardiovascular diseases (arrhythmia, hypertension) without treatment

  10. Cross - hypertensitivity to aspirin or other NSAIDs

  11. History of recent or progressive peptic ulcer/gastrointestinal perforation

  12. Severe liver failure

  13. Severe renal failure without dialysis

  14. Gastrointestinal hemorrhage, recent brain hemorrhage or disorders causing systemichemorrhage

  15. Uncontrolled heart failure

Study Design

Total Participants: 90
Treatment Group(s): 2
Primary Treatment: TD0015 Placebo
Phase: 2
Study Start date:
July 01, 2021
Estimated Completion Date:
November 30, 2024

Study Description

The study objective is to evaluate the safety and efficacy of TD0015 pilulae to determine the optimal dose for investigational product. Phase II analyzes is performed on 90 patients and based on the results of phase II to adjust sample size and study design (if applicable) for phase III.

The trial lasts for ~ 30 months with 6 subject visits (from T0 to T5) and is conducted in National Hospital of Traditional Medicine (Hanoi, Vietnam).

Screening procedure occurs at T0 visit, followed by T1 (15+/-3 days), T2 (30+/-3 days), T3 (45+/-3 days), T4 (60+/-3 days) and T5 (90+/-3 days). The telephone contact visits are performed every 2 weeks by Investigators There are 2 levels of dosages: estimated dose - 5g (arm 1) and 1.5 times (arm 2) of estimated dose - 7.5g. There is also another arm using placebo, thus the trial have 3 arms in total.

As for 3 arms, patients is allowed to use oral NSAIDs (meloxicam 7,5mg x 1-2 tablets/day) when pain is severe.

Treatment time is 60 days. IP is used after a meal, 1 pack/time x 2 times/day.

Connect with a study center

  • National Hospital of Traditional Medicine

    Hanoi, 100000
    Vietnam

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.